Jayant A. Talwalkar, M.D., a hepatologist with the Department of Gastroenterology and Hepatology and the Mayo Clinic Transplant Center in Rochester, Minn., discusses diagnosis, complications, liver transplantation, and Mayo’s role in the development of new diagnostic tests and effective therapies for patients with primary sclerosing cholangitis (PSC).
Dr. Talwalkar notes that PSC is the last major liver disease without effective treatment. There is currently no effective medical therapy to halt disease progression and so avoid complications such as liver failure or bile duct cancer for patients with PSC. PCS is considered an autoimmune condition. It develops silently, most often in patients 40-50 years.
Dr. Talwalkar’s team focuses on clinical trials for the development of diagnostic tests and effective drug therapies for PSC, before transplant is needed. Mayo specialists see several hundred patients with PSC each year.
Clinical trials at Mayo Clinic
Primary sclerosing cholangitis (PSC)
Jayant A. Talwalkar, M.D.